UCB Aktie
| 182,30EUR | -1,50EUR | -0,82% |
WKN: 852738 / ISIN: BE0003739530
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 61,50 |
| Financière de Tubize SA | 36,04 |
| Wellington Management Co. LLP | 6,56 |
| PGIM Jennison International Opportunities Fund | 6,06 |
| Vanguard Health Care Fund | 3,51 |
| UCB SA | 2,44 |
| Government Pension Fund - Global (The) | 1,53 |
| American Funds EuroPacific Growth Fund | 1,06 |
| Vanguard Total International Stock Index Fund | 0,87 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 7 606 | 8 371 | 8 561 | 8 703 | 9 083 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,65 | 0,64 | 0,67 | 0,63 | 0,58 |
Bilanz (in Mio. EUR) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 3 295 | 3 582 | 3 710 | 3 304 | 3 444 |
| Summe Anlagevermögen | 7 786 | 9 737 | 10 500 | 12 564 | 12 095 |
| Summe Aktiva | 11 081 | 13 319 | 14 210 | 15 868 | 15 539 |
Bilanz (in Mio. EUR) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 1 281 | 2 747 | 2 123 | 2 900 | 3 038 |
| Summe Fremdkapital | 4 072 | 6 047 | 5 824 | 6 804 | 6 564 |
| Summe Eigenkapital | 7 009 | 7 272 | 8 386 | 9 064 | 8 975 |
| Summe Passiva | 11 081 | 13 319 | 14 210 | 15 868 | 15 539 |
Adresse
| Allée de la Recherche, 60, 1070 Brussels | |
| Telefon | +32 (2) 559-99-99 |
| Internet | http://www.ucb.com |
Management
|
Antje Witte
Head-Investor Relations |
|
Caroline Vancoillie
Head-Group Finance |
|
Charl van Zyl
Executive Vice President-Neurology Solutions |
|
Charles-Antoine Janssen
Vice Chairman |
|
Cyril Janssen
Director |
|
Dame Kay Davies
Independent Director |
|
Denelle J. Waynick
Executive Vice President & General Counsel |
|
Dolca Thomas
Independent Director |
|
Dominique Baeten
Head-New Patient Value Mission |
|
Emmanuel Caeymaex
Executive VP & Head-Immunology Solutions |
|
Iris Löw-Friedrich
Chief Medical Officer & Executive Vice President |
|
Jan Berger
Independent Director |
|
Jean Luc Fleurial
Chief Human Resources Officer & Executive VP |
|
Jean-Christophe Tellier
Chief Executive Officer & Executive Director |
|
Jonathan M. Peacock
Chairman |
|
Jonkheer Cédric van Rijckevorsel
Director |
|
Kirsten Lund Jurgensen
EVP-Supply & Technology Solutions |
|
Maëlys Castella
Independent Director |
|
Nefertiti Greene
Independent Director |
|
Pierre L. Gurdjian
Independent Director |
|
Raf Remijsen
Head-Treasury & Risk Management |
|
Rodolfo J. Savitzky
Independent Director |
|
Sandrine Dufour
Chief Financial Officer & Executive Vice President |
|
Susan Gasser
Independent Director |
|
Thomas Debeys
Head-Internal Audit |
|
Ulf Arne Wiinberg
Independent Director |
|
Xavier Michel
Group Secretary General |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
